Desmopressin (DDAVP) Enhances Platelet Adhesion to the Extracellular Matrix of Cultured Human Endothelial Cells through Increased Expression of Tissue Factor

Summary

The effect of desmopressin (DDAVP) on thrombogenicity, expression of tissue factor and procoagulant activity (PCA) of extracellular matrix (ECM) generated by human umbilical vein endothelial cells cultures (HUVEC), was studied under different experimental conditions. HUVEC were incubated with DDAVP (1, 5 and 30 ng/ml) and then detached from their ECM. The reactivity towards platelets of this ECM was tested in a perfusion system. Coverslips covered with DD A VP-treated ECMs were inserted in a parallel-plate chamber and exposed to normal blood anticoagulated with low molecular weight heparin (Fragmin®, 20 U/ml). Perfusions were run for 5 min at a shear rate of 800 s¹. Deposition of platelets on ECMs was significantly increased with respect to control ECMs when DDAVP was used at 5 and 30 ng/ml (p <0.05 and p <0.01 respectively). The increase in platelet deposition was prevented by incubation of ECMs with an antibody against human tissue factor prior to perfusion. Immunofluorescence studies positively detected tissue factor antigen on DDAVP derived ECMs. A chromogenic assay performed under standardized conditions revealed a statistically significant increase in the procoagulant activity of the ECMs produced by ECs incubated with 30 ng/ml DDAVP (p <0.01 vs. control samples). Northern blot analysis revealed increased levels of tissue factor mRNA in extracts from ECs exposed to DDAVP. Our data indicate that DDAVP in vitro enhances platelet adhesion to the ECMs through increased expression of tissue factor. A similar increase in the expression of tissue factor might contribute to the in vivo hemostatic effect of DDAVP.

• References

• 1 Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemost Thromb 1986; 8: 19-45
• 2 Rodeghiero F, Castaman G, Mannucci PM. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. Blood Rev 1991; 5: 155-161
• 3 Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. Thromb Haemost 1994; 71: 154-155
• 4 Lethagen S. Desmopressin (DDAVP) and hemostasis. Ann Hematol 1994; 69: 173-180
• 5 David JL. Desmopressin and hemostasis. Regul Peptides 1993; 45: 311-317
• 6 Pfueller SL, Howard MA, White JG, Menon C, Berry EW. Shortening of bleeding time by l-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in gray platelet syndrome. Thromb Haemost 1987; 58: 1060-1063
• 7 Cattaneo M, Moia M, DellaValle P, Castellana P, Mannucci PM. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitates. Evidence for a mechanism of action independent of released von willebrand factor. Blood 1989; 74: 1972-1975
• 8 Watson AJS, Koegh JAB. Effect of l-deamino-8-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron 1982; 32: 49-52
• 9 Escolar G, Cases A, Monteagudo J, Garrido M, López J, Ordinas A, Revert L, Castillo R. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. J Lab Clin Med 1989; 114: 36-42
• 10 Johnstone MT, Andrews JA, Ware JA. Bleeding time prolongation with streptokinase and its reduction with l-deamino-8-arginine vasopressin. Circulation 1990; 82: 2142-2151
• 11 Barnhart MI, Chen S, Lusher JM. DDAVP: Does the drug have a direct effect on the vessel wall? Thromb Res. 1983; 31: 239-53
• 12 Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 71: 629-635
• 13 Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hoffmann T. Evidence for the presence of tissue factor activity on subendothelium. Blood 1989; 73: 968-975
• 14 de Groot PG, Reinders JH, Sixma JJ. Perturbation of human endothelial cells by thrombin or PMA changes the reactivity of their extracellular matrix towards platelets. J Cell Biol 1987; 104: 697-704
• 15 Jaffe EA, Nachman RL, Becker CG. Culture of human endothelial cells derived from umbilical veins. J Clin Invest 1973; 52: 2745-2756
• 16 Aznar-Salatti J, Bastida E, Haas TA, Escolar G, Ordinas A, de GrootPG, Buchanan MR. Platelet adhesion to exposed endothelial cell extracellular matrices is influenced by the method of preparation. Arterioscler Thromb 1991; 11: 436-442
• 17 Fiore MM, Neuenschwander PF, Morrissey JH. An unusual antibody that blocks tissue factor/FVIIa function by inhibiting cleavage only of macro- molecular substrates. Blood 1992; 80: 3127-3134
• 18 Sakariassen KS, Aarts PA, de Groot PG, Houdijk WP, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102: 522-535
• 19 Diaz-Ricart M, Carretero M, Castillo R, Ordinas A, Escolar G. Digital image analysis of platelet-extracellular matrix interactions: studies in von Willebrand disease patients and aspirin-treated donors. Haemostasis 1994; 24: 219-229
• 20 Ravanat C, Archipoff G, Beretz A, Freund G, Cazenave JP, Freyssinet JM. Use of annexin-V to demonstrate the role of phosphatidylserine exposure in the maintenance of haemostatic balance by endothelial cells. Biochem J 1992; 282: 07-13
• 21 Carson SD, Johnson DR. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood 1990; 76: 361-367
• 22 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159
• 23 Sambrook J, Fritsch EF, Maniatis T. molecular cloning: a laboratory manual. 2. nd edit. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY, USA: 1989
• 24 Lehrach H, Diamond D, Wozney JM, Boedtker H. RNA molecular weight determination by gel electrophoresis under denaturating conditions a critical reexamination. Biochemistry 1977; 16: 4743-4751
• 25 Bolhuis PA, Sakariassen KS, Sander HJ, Bouma BN, Sixma JJ. Binding of factor VUI-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med 1981; 97: 568-5676
• 26 Sakariassen KS, Bolhuis PA, Blomback M, Thorell L, Blomback B, Sixma JJ. Association between bleeding time and platelet adherence to artery subendothelium. Thromb Haemost 1984; 52: 144-147
• 27 Sakariassen KS, Nieuwenhuis HK, Sixma JJ. Differentiation of patients with subtype Ilb-like von Willebrand’s disease by means of perfusion experiments with reconstituted blood. Br J Haematol 1985; 59: 459-470
• 28 Sakariassen KS, Nievelstein PF, Coller BS, sixma JJ. The role of platelet membrane glycoproteins lb and Ilb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol 1986; 63: 681-691
• 29 Sixma JJ, Nievelstein PF, Zwaginga JJ, de Groot PG. Adhesion of blood platelets to the extracellular matrix of cultured human endothelial cells. Ann NY Acad Sci 1987; 516: 39-51
• 30 Zwaginga JJ, de Boer HC, IJsseldijk MJ, Kerkhof A, Muller-Berghaus G, Gruhlichhenn J, Sixma JJ, de Groot PG. Thrombogenicity of vascular cells. Comparison between endothelial cells isolated from different sources and smooth muscle cells and fibroblasts. Arteriosclerosis 1990; 10: 437-448
• 31 Zwaginga JJ, Sixma JJ, de Groot PG. Activation of endothelial cells induces platelet thrombus formation on their matrix Studies of new in vitro thrombosis model with low molecular weight heparin as anticoagulant. Arteriosclerosis 1990; 10: 49-61
• 32 Rao LVM, Rapaport SI, Bajaj SP. Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood 1986; 65: 685-691
• 33 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-1097
• 34 Nawroth P, Stern D. Modulation of endothelial cell hemostatic properties by tumour necrosis factor. J Exp Med 1986; 163: 740-745
• 35 Mulder AB, Karin SM, Heggepaping KSM, Magielse CPE, Blom NR, Smit JW, Vandermeer J, Halie MR, Bom VJJ. Tumor necrosis factor α-induced endothelial tissue factor is located on the cell surface rather than in the subendothelial matrix. Blood 1994; 84: 1559-1566
• 36 Colucci M, Balconi G, Lorenzet T, Petra A, Locati D. Cultures human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-1896
• 37 Nemerson Y. Tissue factor and haemostasis. Blood 1988; 71: 01-08
• 38 Salatti JA, Fenton J, Anton P, Sakariassen KS. α-Thrombin bound to extracellular endothelial matrix induces pronounced fibrin deposition and platelet thrombus growth in flowing non-anticoagulated human blood. Blood Coag Fibrinol 1994; 5: 561-566
• 39 Orvim U, Roald HE, Stephens RW, Roos N, Sakariassen KS. Tissue factor induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow. Arterioscler Thromb 1994; 14: 1976-1983
• 40 Moffat EH, Giddings JC, Bloom AL. The effect of l-deamino-8-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. Br J Haematol 1984; 57: 651-662
• 41 Stel HV, Sakariassen KS, de Groot PG, van Mourik JA, Sixma JJ. Von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985; 65: 85-90